Glioblastoma Phase 2/3 Trials + FDA Status + PubMed

Created by

Clearfeed Labs

Actor

ClinicalTrials.gov Scraper & Trial Change Tracker: PubMed + FDA

Recruiting Phase 2 and 3 glioblastoma trials from the official ClinicalTrials.gov API, with linked PubMed papers and Drugs@FDA approval status of the studied drugs.

Try for free

ClinicalTrials.gov Scraper & Trial Change Tracker: PubMed + FDAclearfeedlabs/clinical-trial-tracker

Row type

Nct id

Title

Overall status

+12 fields

Input

Conditions / diseases:glioblastoma

Recruitment status:RECRUITING

Phases:PHASE2+1

Add-on: linked PubMed publications (+$0.002/trial):true

Add-on: FDA approval status of studied drugs (+$0.002/trial):true

Max trials:25

Output fields

Row type

Nct id

Title

Overall status

Phases

Conditions

Lead sponsor

Sponsor class

Enrollment

Primary completion date

Has results

Recruiting site count

Countries

Change summary

Publication count

Url

How it works

Sign up on Apify or log in

The ClinicalTrials.gov Scraper & Trial Change Tracker: PubMed + FDA Actor is ready to run with the inputs already set for "Glioblastoma Phase 2/3 Trials + FDA Status + PubMed". Sign up or log in and you'll land in Apify Console with a copy of this exact task.

Start the "Glioblastoma Phase 2/3 Trials + FDA Status + PubMed" task

The ClinicalTrials.gov Scraper & Trial Change Tracker: PubMed + FDA Actor will start running based on the input automatically. You can also change all the input fields, like conditions / diseases, recruitment status, and more, to match your specific use case.

Receive the "Glioblastoma Phase 2/3 Trials + FDA Status + PubMed" output

Monitor the progress in real time. You will be notified as soon as your dataset is complete and ready for review. Each result includes data such as row type, nct id, title, and more.

Integrate into your workflow

The final output is delivered in JSON, CSV, or Excel format, ready to be plugged into your workflow. You can also run the "Glioblastoma Phase 2/3 Trials + FDA Status + PubMed" task via API.